Get the Stockscreener App
58.78
0.54%
-0.32
After Hours:
58.78
Catalent Inc stock is traded at $58.78, with a volume of 1.50M.
It is down -0.54% in the last 24 hours and down -2.50% over the past month.
Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.
See More
Previous Close:
$59.10
Open:
$59.1
24h Volume:
1.50M
Relative Volume:
0.98
Market Cap:
$10.67B
Revenue:
$4.42B
Net Income/Loss:
$-413.00M
P/E Ratio:
-45.22
EPS:
-1.3
Net Cash Flow:
$99.00M
1W Performance:
-1.14%
1M Performance:
-2.50%
6M Performance:
+6.16%
1Y Performance:
+47.43%
1-Day Range:
$58.58
$59.13
1-Week Range:
$58.58
$59.76
52-Week Range:
$36.74
$61.20
Catalent Inc Stock (CTLT) Company Profile
Name
Catalent Inc
Sector
Phone
(732) 537-6200
Address
14 SCHOOLHOUSE ROAD, SOMERSET, NJ
Compare CTLT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| CTLT | 58.78 | 10.67B | 4.42B | -413.00M | 99.00M | -1.30 |
| ZTS | 176.42 | 79.51B | 9.15B | 2.43B | 2.31B | 4.92 |
| TAK | 13.53 | 42.89B | 30.27B | 1.93B | 3.45B | 0.444 |
| HLN | 9.43 | 42.57B | 14.26B | 1.55B | 0 | 0.3327 |
| TEVA | 16.49 | 18.51B | 16.77B | -959.00M | 1.37B | -2.00 |
| VTRS | 13.00 | 15.37B | 15.24B | -646.50M | 1.88B | 1.53 |
Catalent Inc Stock (CTLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-16-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-05-23 | Upgrade | Argus | Hold → Buy |
| Jul-20-23 | Initiated | Wells Fargo | Equal Weight |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jun-14-23 | Downgrade | Jefferies | Buy → Hold |
| May-22-23 | Downgrade | JP Morgan | Overweight → Neutral |
| May-15-23 | Downgrade | Deutsche Bank | Buy → Hold |
| May-08-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Apr-17-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-14-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-10-23 | Upgrade | Deutsche Bank | Hold → Buy |
| Apr-03-23 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-22 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Nov-07-22 | Downgrade | Argus | Buy → Hold |
| Nov-02-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-16-21 | Initiated | Barclays | Overweight |
| Dec-10-20 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Jun-25-20 | Initiated | Argus | Buy |
| Apr-21-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-02-20 | Initiated | Deutsche Bank | Hold |
| Oct-17-19 | Resumed | Stephens | Overweight |
| Aug-28-19 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jun-21-19 | Upgrade | Jefferies | Hold → Buy |
| Apr-16-19 | Upgrade | UBS | Neutral → Buy |
| Nov-07-18 | Upgrade | First Analysis Sec | Neutral → Outperform |
| Oct-09-18 | Initiated | UBS | Neutral |
| Mar-28-18 | Upgrade | KeyBanc Capital Mkts | Sector Weight → Overweight |
| Mar-21-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Feb-06-18 | Downgrade | Stephens | Overweight → Equal-Weight |
| Sep-21-17 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-13-17 | Initiated | Needham | Hold |
| Sep-08-17 | Downgrade | KeyBanc Capital Mkts | Overweight → Sector Weight |
| Dec-01-16 | Initiated | Goldman | Neutral |
| Oct-20-16 | Initiated | KeyBanc Capital Mkts | Overweight |
| Jun-21-16 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Jun-20-16 | Upgrade | BofA/Merrill | Neutral → Buy |
View All
Catalent Inc Stock (CTLT) Latest News
Quest Partners LLC Purchases 36,652 Shares of Catalent, Inc. (NYSE:CTLT) - MarketBeat
Sumitomo Mitsui Trust Group Inc. Raises Stock Position in Catalent, Inc. (NYSE:CTLT) - MarketBeat
500,000 Shares in Catalent, Inc. (NYSE:CTLT) Purchased by Mizuho Markets Americas LLC - MarketBeat
GMP Cell Banking Market Hits New High | Major Giants Catalent, BioIVT, Abzena - openPR
Curi RMB Capital LLC Trims Stake in Catalent, Inc. (NYSE:CTLT) - MarketBeat
Nomura Holdings Inc's Strategic Reduction in Catalent Inc Shares - GuruFocus.com
Catalent director Ryan Michelle R sells $167,160 in stock By Investing.com - Investing.com Nigeria
Catalent director Ryan Michelle R sells $167,160 in stock - Investing.com India
Catalent, Inc. (NYSE:CTLT) Shares Acquired by ING Groep NV - MarketBeat
Janus Henderson Group PLC's Strategic Reduction in Catalent Inc Holdings - GuruFocus.com
High Potency API Contract Manufacturing Market Forecast, 2025-2030 - GlobeNewswire Inc.
Catalent (NYSE:CTLT) Stock Rating Upgraded by StockNews.com - MarketBeat
EU regulators quiz Novo Nordisk, Catalent rivals on $16.5 billion deal - KFGO
Capital World Investors Expands Stake in Catalent Inc - GuruFocus.com
EU regulators seek info from rivals, customers in Catalent sale to Novo HoldingsReuters - Seeking Alpha
EU regulators quiz Novo Nordisk, Catalent rivals on $16.5 bln deal - Reuters
Catalent's Stock Gains on Q4 Earnings Beat, Gross Margin Up - MSN
Catalent's SWOT analysis: stock outlook amid acquisition talks, regulatory shifts - Investing.com Nigeria
Catalent's Stock Gains Despite Q1 Earnings Miss, Gross Margin Up - MSN
Catalent, Inc. (NYSE:CTLT) Shares Acquired by Van ECK Associates Corp - MarketBeat
Olympiad Research LP Boosts Holdings in Catalent, Inc. (NYSE:CTLT) - MarketBeat
Catalent Inc Reports Q1 Fiscal 2025 Earnings: $1.02 Billion Reve - GuruFocus.com
Brokerages Set Catalent, Inc. (NYSE:CTLT) Price Target at $59.83 - MarketBeat
EU antitrust regulators to rule on Novo's Catalent buy by Dec. 6 - MSN
Novo Holdings Acquires Catalent Despite Financial Setback - Finimize
Catalent reports Q1 loss, misses market expectations - MSN
Catalent (CTLT) Reports Q1 Loss, Lags Revenue Estimates - MSN
Catalent Inc. Reports Q1 Fiscal 2025 Results - TipRanks
Catalent: Fiscal Q1 Earnings Snapshot - The Washington Post
Catalent misses Q1 revenue estimates ahead of $16.5 bln deal close with Novo Holdings - Reuters
Catalent misses Q1 revenue estimates ahead of $16.5 billion deal close with Novo Holdings - Yahoo Finance
Catalent (CTLT) Misses Q1 EPS by 16c, Misses on Revenue - StreetInsider.com
Catalent Inc earnings missed by $0.16, revenue fell short of estimates - Investing.com South Africa
Catalent reports Q1 EPS (13c), consensus 5c - TipRanks
Catalent, Inc. Reports First Quarter Fiscal 2025 Results - Yahoo Finance
Novo Holdings planned $16.5B planned acquisitions of Catalent gets EU inquiry - MSN
Life Sciences BPO Market Set to Witness Significant Growth by 2024-2031:Catalent, Inc., Covance, Inc., Fareva, - EIN News
Commit To Buy Catalent At $55, Earn 1.5% Annualized Using Options - Nasdaq
Assenagon Asset Management S.A. Has $330,000 Position in Catalent, Inc. (NYSE:CTLT) - MarketBeat
EU antitrust regulators to decide on Novo's Catalent buy by Dec. 6 - Marketscreener.com
Catalent Acquisition By Novo Holdings: Evolution Of The Industry(?) - Contract Pharma
Americana Partners LLC Buys New Shares in Catalent, Inc. (NYSE:CTLT) - MarketBeat
Catalent, Inc. (NYSE:CTLT) Shares Sold by Norris Perne & French LLP MI - MarketBeat
Catalent Inc Stock (CTLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):